What reconstitution means

Reconstitution is the process of dissolving a lyophilized (freeze-dried) solid in a suitable diluent to yield a solution or suspension suitable for administration. It is not merely mixing: it involves wetting, swelling, dissolution of a porous solid matrix, and often hydration and refolding of the peptide or protein.

Dissolution occurs when the free energy of the solute--solvent interaction is lower than that of the solute--solute interactions in the solid. For a lyophilized peptide formulation:

• The lyophilized cake is a porous, amorphous or partially crystalline solid with a very large specific surface area (typically several m^2/g). This high surface area facilitates rapid water vapor sorption when the vial is opened and when diluent is added.

• Dissolution is driven by the Gibbs free energy of mixing. For ideal solutions, ΔG_mix = RT (n₁ ln x₁ + n₂ ln x₂). Real peptide solutions deviate substantially from ideality due to charge, hydrogen bonding, hydrophobic interactions, and excluded-volume effects.

• The rate of dissolution follows the Nernst--Brunner modification of the Noyes--Whitney equation: dC/dt = DA(C_s - C) / (Vh), where D is the diffusion coefficient, A is the surface area, C_s is the saturation solubility, C is the bulk concentration, V is the volume, and h is the boundary-layer thickness.

The diluent is selected to match the formulation's pH, tonicity, and solubilization requirements. Common diluents include:

• Sterile Water for Injection (SWFI): Sterile, non-pyrogenic water packaged in single-dose containers. Used as a diluent when specified by the exact product label. SWFI contains no antimicrobial preservative and is intended for single use only; any unused portion must be discarded.

• Bacteriostatic Water for Injection (BWFI): Sterile water containing 0.9% benzyl alcohol (or other antimicrobial preservative). BWFI is only suitable when the formulation is compatible with the preservative and when the product is intended for multi-dose use. Benzyl alcohol is contraindicated in neonates. Water for Injection (WFI) is bulk pharmaceutical-grade water used in manufacturing and is not administration-ready.

• Sodium chloride 0.9% injection: Provides isotonicity; used when the lyophilized formulation contains no or insufficient bulking agent to achieve tonicity.

• Dextrose 5% in water (D5W): Provides isotonicity and energy; used in specific approved products.

No diluent is universally interchangeable. Changing the diluent recommended by the manufacturer can alter pH, tonicity, and compatibility, causing precipitation, aggregation, or loss of potency.

When diluent is first added to a lyophilized cake, the liquid must displace air from the pores. The rate of wetting depends on:

• Contact angle between the diluent and the cake material

• Pore size distribution (typically 10--100 µm for lyophilized products)

• Surface tension of the diluent (reduced by surfactants, if present in the formulation)

The cake may initially float or resist wetting if the contact angle exceeds 90 degrees. A short hold time allows capillary action to draw diluent into the pores. Whether agitation is acceptable is product-specific and must follow the validated label instructions.

Peptides and proteins in solution are subject to:

• Aggregation: Non-covalent (hydrophobic, electrostatic) or covalent (disulfide scrambling, cross-linking) association of monomers. Aggregation can be accelerated by:

  • High local peptide concentration during reconstitution (if diluent is added too slowly or to one spot)

  • Shaking or vortexing (air--liquid interface denaturation)

  • pH excursions if the diluent pH differs from the formulation pH

  • Presence of metal ions or leachables from container closure

• Adsorption: Peptide loss to container surfaces (glass, rubber stopper, polymer bag). Adsorption is governed by electrostatic and hydrophobic interactions between the peptide and the surface. In siliconized glass vials, hydrophobic peptides may partition into the silicone oil layer. Polysorbate surfactants (if present in the formulation) compete for surface sites and reduce adsorption.

Reconstitution temperature affects:

• Solubility: Most peptides show increased solubility at higher temperature, but some (especially those with extensive beta-sheet structure) may aggregate more readily.

• Dissolution rate: Diffusion coefficient increases roughly 2--3% per degree Celsius; viscosity of the diluent decreases.

• Stability: Peptide degradation (hydrolysis, deamidation) often accelerates at elevated temperature, but the permitted post-reconstitution temperature and holding time are product-specific and cannot be generalized.

The label-specified temperature range for reconstitution (e.g., "allow to reach room temperature" or "reconstitute with cold diluent") is product-specific and validated during development.

Some lyophilized cakes form a temporary gel-like phase during reconstitution. Whether that appearance is acceptable, and whether agitation is permitted, can only be determined from the exact product's validated instructions. Visual inspection may detect gross particles or discoloration but cannot establish potency, sterility, endotoxin status, or overall suitability for administration.

Two formulations containing the same peptide at the same nominal mass may differ in:

• Cake porosity and specific surface area (affected by freeze-drying cycle parameters)

• Excipient composition (buffer species, tonicity modifier, bulking agent, surfactant, preservative)

• Amorphous vs. crystalline state of excipients (e.g., mannitol can be crystalline, amorphous, or a mixture)

• Residual moisture content (affects cake density and hydration rate)

• Vial headspace gas composition (air vs. nitrogen vs. argon)

These variables alter reconstitution time, clarity, and the risk of aggregation. Therefore, reconstitution instructions are product-specific and cannot be generalized by peptide mass alone.

1. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969--975. https://doi.org/10.1023/a:1012180707283

2. USP General Chapter <1151> Pharmaceutical Dosage Forms. USP–NF. Rockville, MD: United States Pharmacopeia; 2026.

3. FDA. Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. 2008. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

4. Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20(6):708--714. https://doi.org/10.1016/j.copbio.2009.10.006

5. Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog. 2008;24(3):504--514. https://doi.org/10.1021/bp070462h

6. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1--2):1--30. https://doi.org/10.1016/j.ijpharm.2004.11.014